A House committee approves a bill to ban all flavored tobacco products; anal cancer rates are on the rise; the debate continues over competing healthcare measures.
Late Tuesday, the House Energy and Commerce Committee approved a bill to ban all flavored tobacco products, increase the age to buy to 21, and ban online sales, according to Politico. This bill, aimed to curb teens’ soaring use of tobacco products, especially vaping products, is viewed as being more aggressive than President Donald Trump’s flavor ban, which he put on hold this week fearing loss of votes. The American Medical Association is also calling for a ban in light of 2 lawsuits against vaping giant Juul for unfairly targeting teens, according to The New York Times.
Study results appearing in the Journal of the National Cancer Institute show a rising trend in deaths from anal cancer over the past 15 years, according to CNN, among people aged 50 or older. With most cases of anal cancer linked to the human papillomavirus (HPV), per the CDC, and risk factors for the historically rare cancer now including HIV, the authors are calling for improved screening and wider HPV vaccination efforts.
Leaders of both political parties agree that patients need protection from oversized medical bills if they happen to require an emergency department visit and their treating physician in not in their network, according the The Hill. A measure from the Senate Health Committee (SHC) would set insurer rates, but doctors and hospitals fear it could cut their payments; they want the rates decided via arbitration. The House Energy and Commerce Committee has a bill, too, and is hoping to come to an agreement with the SHC by December.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen